Research programme: naloxegol/opioid analgesic combination - AstraZeneca/Nektar

Drug Profile

Research programme: naloxegol/opioid analgesic combination - AstraZeneca/Nektar

Alternative Names: Naloxegol/opioid; NKTR-118/opioid - Nektar Therapeutics/AstraZeneca; NKTR-119

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nektar Therapeutics
  • Developer AstraZeneca; Nektar Therapeutics
  • Class Opioid analgesics
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Pain

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in USA (PO)
  • 11 Jun 2014 The Anesthetic and Analgesic Drug Products Advisory Committee of the US FDA schedules a meeting to assess potential cardiovascular risk associated with peripherally-acting opioid receptor antagonists, including naloxegol
  • 14 Jan 2014 Preclinical development of NKTR 119 is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top